FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment
Roche announced the FDA approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for initial treatment of adults with extensive-stage small cell lung cancer. This approval is based on results from the Phase III IMpower133 study. March 19, 2019